Navigation Links
Transdel Pharmaceuticals, Inc. Retains The Investor Relations Group
Date:11/10/2008

ursuing the development of cosmeceutical products.

"With our lead product, Ketotransdel(TM), in Phase 3 clinical trial, and a strong pipeline of co-development opportunities utilizing our Transdel(TM) platform technology, this is an opportune time to increase our visibility within the investment and media community," said Dr. Juliet Singh, President and CEO of Transdel Pharmaceuticals. "As we remain focused on our clinical program and growth objectives, we look forward to IRG communicating our progress to the appropriate target audiences."

About Transdel Pharmaceuticals, Inc.

Transdel Pharmaceuticals, Inc. (OTCBB: TDLP - News) is a specialty pharmaceutical company developing non-invasive, topically-delivered medications. The Company's innovative patented proprietary Transdel(TM) cream formulation technology is designed to facilitate the effective penetration of drugs through the tough skin barrier to reach the target underlying tissues. In the case of Ketotransdel(TM), the Transdel(TM) cream allows the active ingredient ketoprofen to reach the target soft tissue and exert its well-known anti-inflammatory and analgesic effects. The Company is also investigating other drug candidates and treatments for transdermal delivery using the patented Transdel(TM) platform technology for products in pain management and other therapeutic areas. For more information, please visit http://www.transdelpharma.com.

About The Investor Relations Group, Inc.

The Investor Relations Group, Inc. (IRG) offers a full-service corporate communications program designed to suit the many unique needs of public companies. The program utilizes a proprietary, targeted approach to reach institutional investors, analysts, and the media-at-large. For further information, please visit the company's website at http://www.investorrelationsgroup.com.
'/>"/>

SOURCE Transdel Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related biology technology :

1. Transdel Pharmaceuticals Closes $4 Million Financing
2. Transdel Pharmaceuticals to Present at Rodman & Renshaw 10th Annual Global Healthcare Conference
3. Drug Royalty Corporation (DRC) Announces Acquisition Regarding PEG-INTRON(R) From Enzon Pharmaceuticals, Inc. (ENZN)
4. Prestwick Pharmaceuticals, Inc. Continues to Build Management Team With Appointment of Martin Stogniew, Ph.D. as Executive Vice President, Chief Technology Officer
5. Keryx Biopharmaceuticals, Inc. Announces Appointment of Michael P. Tarnok to Board of Directors
6. Keryx Biopharmaceuticals, Inc. Announces Conference Call to Discuss Strategic Alliance
7. Keryx Biopharmaceuticals, Inc. Enters into Licensing Agreement with Japan Tobacco and Torii Pharmaceutical for Development and Commercialization of Hyperphosphatemia Drug in Japan
8. NPS Pharmaceuticals, Inc. Announces an Increase in Tender Offer Price for Its 3.0% Convertible Notes Due 2008 and Extends Expiration Date Until October 17, 2007
9. Alseres Pharmaceuticals, Inc. to Present at Bio Investor Forum 2007 Annual Meeting
10. Jazz Pharmaceuticals, Inc. Announces Changes to its Board of Directors
11. Alseres Pharmaceuticals, Inc. to Present at Windhovers Therapeutic Area Partnerships Conference
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Biology Technology:Olympics 2016, World Cup 2014, But First – Adventus Brasil 2009 2Olympics 2016, World Cup 2014, But First – Adventus Brasil 2009 3Olympics 2016, World Cup 2014, But First – Adventus Brasil 2009 4Dendreon Announces Proposed Public Offering of Common Stock 2Dendreon Announces Proposed Public Offering of Common Stock 3Transgenomic Announces the Commercial Launch of SURVEYOR(R) Scan K-RAS Mutation Detection Kit 2Transgenomic Announces the Commercial Launch of SURVEYOR(R) Scan K-RAS Mutation Detection Kit 3Transgenomic Announces the Commercial Launch of SURVEYOR(R) Scan K-RAS Mutation Detection Kit 4Reportlinker Adds Microplate Instrumentation & Supplies - A Global Market Perspective 2Reportlinker Adds Microplate Instrumentation & Supplies - A Global Market Perspective 3Reportlinker Adds Microplate Instrumentation & Supplies - A Global Market Perspective 4Reportlinker Adds Microplate Instrumentation & Supplies - A Global Market Perspective 5Reportlinker Adds Microplate Instrumentation & Supplies - A Global Market Perspective 6Reportlinker Adds Microplate Instrumentation & Supplies - A Global Market Perspective 7Reportlinker Adds Microplate Instrumentation & Supplies - A Global Market Perspective 8
Breaking Biology News(10 mins):Abundance of a look-alike species clouds population status of a million dollar fish 2Abundance of a look-alike species clouds population status of a million dollar fish 3Charles Darwin: More than the origin 2Charles Darwin: More than the origin 3Oceans day at International Climate Change Conference 25 Simple Ways to Take 10 Years Off Your Face 55377 15 Simple Ways to Take 10 Years Off Your Face 55377 25 Simple Ways to Take 10 Years Off Your Face 55377 35 Simple Ways to Take 10 Years Off Your Face 55377 4Environmental Tectonics Corporations BioMedical Systems Division Announces First BARA MED 28R 29 Monoplace Hyperbaric Chamber Sale in Romania 55373 1Environmental Tectonics Corporations BioMedical Systems Division Announces First BARA MED 28R 29 Monoplace Hyperbaric Chamber Sale in Romania 55373 2Environmental Tectonics Corporations BioMedical Systems Division Announces First BARA MED 28R 29 Monoplace Hyperbaric Chamber Sale in Romania 55373 3Environmental Tectonics Corporations BioMedical Systems Division Announces First BARA MED 28R 29 Monoplace Hyperbaric Chamber Sale in Romania 55373 4Many Hospitals Are Not Ready for H1N1 3A Nurse Survey Shows Deficiencies in Hospital Swine Flu Readiness 55369 1Many Hospitals Are Not Ready for H1N1 3A Nurse Survey Shows Deficiencies in Hospital Swine Flu Readiness 55369 2Many Hospitals Are Not Ready for H1N1 3A Nurse Survey Shows Deficiencies in Hospital Swine Flu Readiness 55369 3